Skip to main content
OpenTrials
Completed

NCT Number: NCT01902394

The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses

The purpose of this study is to determine if substituting whole grains for refined grains in the diets of healthy adults over a period of 6 weeks alters the composition of the bacteria in the gut, and has beneficial effects on immune function, digestive health, cardiovascular health, regulation of body weight and composition, and vitamin K status.

The investigators hypothesize that whole grain consumption over a period of 6 weeks will alter the gut microflora toward a more beneficial bacterial profile, improve the immune response while reducing oxidative stress and inflammatory markers, have favorable effects on factors influencing the regulation of body weight and composition,increase bacterial vitamin K synthesis, and beneficially effect surrogate markers of cholesterol synthesis/absorption, vitamin D concentrations, and whole genome DNA methylation patterns. In statin users it is hypothesized that, consumption of whole grains will alter statin pharmacokinetics by decreasing rate of statin absorption, resulting in more sustained plasma concentrations.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

HNCRA at Tufts University

Boston, Massachusetts, 02111, United States

About this study

This study is a randomized parallel-arm trial using a six-week dietary intervention following a 2 week run-in period. Healthy volunteers will be randomized to two groups (n=40/group), and consume either a diet rich in whole grains or a diet rich in refined grains provided at estimated energy requirements for 6 weeks. Outcomes will be measured during the run-in period and at week 6 of the intervention. To control for variation in microbiota an additional 10 volunteers will serve as "negative controls" and not undergo any diet intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Subjects Inclusion Criteria

  • Healthy male and female subjects aged 40-65 y (women must be > 1 year postmenopausal or had both ovaries removed, if premenopausal).
  • Body mass index (BMI) 20-35 kg/m.2
  • Pass screening blood and urine tests
  • Creatinine ≤ 1.5 mg/dL
  • glutamic oxaloacetic transaminase/serum glutamate pyruvate transaminase/total bilirubin ≤ twice the upper limit of normal range
  • Fasting glucose <125 mg/dL
  • hematocrit ≥ 32%
  • white blood cell count ≥ 1.8 x 103/mm3 (M)
  • PLT ≥ 100 x 103/mm3 (thou/µL)
  • Must be willing to be randomized.
  • Those randomized to either the WG or RG groups must be willing to consume only study foods and beverages provided.

Exclusion criteria

  • Self reported weight change >4kg within the past 3 months.
  • Have participated in a weight loss program within the last 3-months; eligible if in weight reduction program to maintain body weight.
  • Not willing to reduce habitual daily fiber intake (including prebiotics) within 2 wk prior to enrollment to < ~7g/1000kcal/d for men, or <~8g/1000kcal/d for women if currently consuming greater amounts.
  • Not willing to stop consumption of probiotic or prebiotic supplements within 2 weeks prior to start of study if currently taking these, as well as during study participation.
  • Vegetarian diet.
  • Not willing to stop taking multivitamins, and supplements (with the exception of vitamin D and calcium), including fish oil or n-3 fatty acids and herbal supplements, for 30 days prior to or during study participation, if currently taking these.
  • Regular use of laxatives, stool softeners, or anti-diarrheal medications, and medications influencing food intake and/or appetite.
  • Not willing to undergo a 3-month washout period after colonoscopy prior to enrollment, and not willing to defer colonoscopy until after study completion.
  • Eating disorder within the past 10 years.
  • Disinhibited eating behavior as indicated by a score above 12 on the Three Factor Eating Questionnaire.
  • Food allergies or aversions or other issues with foods that would preclude use of study diets, including gluten, milk, nuts, or eggs.
  • Individuals identified during screening as having barriers expected to deter compliance with dietary requirements (e.g., stated dislike of study foods, inadequate resources to store and reheat meals, inability to adhere to food pick-up schedule).
  • Alcohol consumption >2 drinks per day.
  • Not willing to abstain from alcohol consumption during the study.
  • Smoking or using nicotine containing products in the last 6 months.
  • Use of aspirin, non-steroidal anti-inflammatory medications (NSAIDs) or antihistamine prescribed by a physician or clinician, or the inability to discontinue the use of these substances for 72 hrs before first day blood draw until 48 hrs after DTH implant (i.e. after second reading).
  • Use of anabolic steroids, insulin, growth hormone or testosterone.
  • Type I or type II diabetes.
  • Uncontrolled major illnesses. (Will include if stable on drugs used to control cardiovascular, liver, and renal diseases, asthma, and dysphagia).
  • Current use of proton pump inhibitors and H2 blockers to control acid-reflux/heart burn
  • Use of medications which interfere with energy metabolism including oral glycemic agents and insulin.
  • Uncontrolled hypertension as determined by study physician or nurse.
  • Use of immunosuppressive drugs.
  • Active cancer or current cancer diagnosis (except non-melanoma skin cancer).
  • Active infection within 2 weeks of study enrollment, blood draws or skin tests; however, may participate if admission is postponed or study activity is rescheduled > 2 weeks after resolution of symptoms.
  • Any antibiotic use within the past 3 months, except topical antibiotic use.
  • History of dysphagia, malabsorptive disorders, inflammatory bowel disease or other gastrointestinal disorders such as ulcerative colitis, Crohn's disease, celiac disease , chronic diarrhea or constipation.
  • Gastric bypass or other surgery for weight loss.
  • Splenectomy or partial splenectomy.
  • Autoimmune diseases such as rheumatoid arthritis and psoriasis. Autoimmune thyroid disease that has been treated and with stable replacement doses is not an exclusion.
  • Taking warfarin or coumadin any time during the previous 6 months.
  • Current diagnosis of or treatment for psychosis (i.e. schizophrenia, etc.). Include depression if has been stable on treatment regimen for > 6 months.
  • Blindness or deafness not corrected with use of glasses and hearing aids.
  • Does not speak English; due to insufficient funds to hire a translator and to get all study materials translated into another language to allow us to recruit non-English speaking participants non-English speakers will not be eligible to participate.

Treatment and study plan

Whole grains

Other

Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.

Refined grains

Other

Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.

Primary outcomes

  1. change in T Cell-mediated immunity

    Time frame: week 2 of washout diet and week 6 of diet intervention

    Delayed-type hypersensitivity (DTH) and lymphocyte proliferation will be measured at baseline (week 2 of washout period) and at week-6 of the diet intervention to assess adaptive immune function, specifically T cell-mediated immunity.

  2. change in Lymphocyte proliferation

    Time frame: week 2 of washout diet and week 6 of diet intervention

    Whole blood collected at baseline (week 2 of washout period) and at week-6 of the diet intervention will be investigated for the ability of lymphocytes to proliferate by quantifying the incorporation of tritium following mitogen stimulation.

  3. change in Natural Killer Function

    Time frame: week 2 of washout diet and week 6 of diet intervention

    The ability of peripheral blood mononuclear cells to bind and kill leukemia cells will be measured at baseline (week 2 of washout period) and at week-6 of the diet intervention

  4. change in Cytokines

    Time frame: week 2 of washout diet and week 6 of diet intervention

    Peripheral blood and stool samples will be analyzed at baseline (week 2 of washout diet) and week-6 of diet intervention for cytokines.

  5. change in Salivary immunoglobulin A (IgA)

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Salivary IgA will be analyzed at baseline (week 2 of washout period) and at week-6 of the diet intervention.

Secondary outcomes

  1. change in gut microbiota composition

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Phylogenetic composition and relative abundance of bacteria in stool will be analyzed from 24-hour fresh sample collected at baseline (week 2 of washout diet) and at week 6 of intervention diet

  2. change in cardiovascular health risk factors

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Consumption of the whole grain (WG) diet will be beneficial for multiple outcomes of cardiovascular health including a favorable blood lipid profile (low density lipoprotein, very low-density lipoprotein, high density lipoprotein, total cholesterol and triglycerides), and a decrease in blood pressure, and in oxidative stress status (secondary hypothesis).

  3. change in vitamin K status

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Fecal menaquinones concentrations; Fasting serum phylloquinone and menaquinones concentration from 72-hour stool collected at baseline (week 2 of washout diet) and at week 6 of intervention diet

  4. change in body composition

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Fat and fat free mass; waist and hip circumference

  5. change in appetite

    Time frame: Weekly for 8 weeks

    Visual analog scales to assess hunger, fullness and satisfaction while on the study diet

  6. change in fasting gut hormone concentration

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Plasma glucagon-like peptide-1 and peptide-YY will be measured from blood samples collected at baseline (week 2 of washout diet) and week 6 of intervention diet

  7. change in fasting serum leptin

    Time frame: week 2 of washout diet and week 6 of intervention diet

  8. change in glycemic regulation

    Time frame: week 2 of washout diet and week 6 of intervention diet

    48 hr continuous glucose monitoring; fasting serum glucose; fasting serum insulin; HOMA-IR

  9. change in resting energy metabolism

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Resting energy expenditure; substrate oxidation at rest

  10. change in eating behaviors

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Questionnaires will be administered at baseline (week 2 of washout diet) and week 6 of intervention diet

  11. change in quality of life

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Questionnaires will be administered at baseline (week 2 of washout diet) and week 6 of intervention diet

  12. change in breath hydrogen and methane

    Time frame: week 2 of washout diet and week 6 of intervention diet

  13. change in stool pH

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet

  14. change in 72hr fecal weight

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet

  15. change in stool water content

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet

  16. change in total stool anaerobic and aerobic bacterial counts

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet

  17. change in stool energy content

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Will be measured from 72-hour stool sample collected at baseline (week 2 of washout diet) and week 6 of intervention diet

  18. change in DNA methylation

    Time frame: week 2 of washout diet and week 6 of intervention diet

  19. change in concentrations of the cholesterol synthesis (squalene, desmosterol, lathosterol) and absorption (campesterol, sitosterol, cholestanol) markers

    Time frame: week 2 of washout diet and week 6 of intervention diet

    Plasma squalene, desmosterol, lathosterol), campesterol, sitosterol, and cholestanol concentrations will be measured at baseline (week 2 of washout diet) and week 6 of intervention diet

  20. change in serum vitamin D

    Time frame: week 2 of washout diet and week 6 of intervention diet

Sponsors and collaborators

Lead sponsor

Tufts University

Other

Collaborators

  • General Mills
  • Tufts Medical Center

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Jul 18, 2013
Registry last updated
May 21, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.